Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

PRL-8-53

This article is a stubmissing:
Subjective Effects
Pharmacology
Interactions
Tolerance
History & Culture
Legality
PRL-8-53 molecule structurePRL-8-53 molecule structure

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold2-3 mg
Light3-5 mg
Moderate5-10 mg
Strong10-20 mg
Heavy20+ mg

Starting with a low dose and increasing gradually is strongly recommended due to limited human safety data.

Duration

After Effects1-12 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Liebermann(LB)
white → yellow2
Marquis(MQ)
No reaction
No reaction
Mecke(ME)
No reaction
No reaction
Mandelin(MD)
No reaction
No reaction
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

PRL-8-53 is characterized as relatively non-toxic in animal data, with 860 mg/kg reported as the mouse oral LD50.

LD50 Data
SpeciesRouteValue
mouseoral860 mg/kg
cardiovascular

Doses above 8 mg/kg caused brief hypotensive effects in canines.

central nervous system

High doses depressed motor activity in rats and mice; the mouse ED50 for 50% motor reduction was 160 mg/kg.

History & Culture

History & Culture not written up yet

Legality

Legality not written up yet

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the PRL-8-53 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.